Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Elena A B Azizan, Clinical Pharmacology Unit, Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, United Kingdom
  • Hanne Poulsen
  • Petronel Tuluc, Pharmacology and Toxicology, Institute of Pharmacy, Center for Molecular Biosciences, University of Innsbruck, Austria
  • Junhua Zhou, Clinical Pharmacology Unit, Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, United Kingdom
  • Michael Clausen, National Veterinary Institute, Denmark
  • Andreas Lieb, Pharmacology and Toxicology, Institute of Pharmacy, Center for Molecular Biosciences, University of Innsbruck, Austria
  • Carmela Maniero, Clinical Pharmacology Unit, Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, United Kingdom
  • Sumedha Garg, University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Hospital, United Kingdom
  • Elena G Bochukova, University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Hospital, United Kingdom
  • Wanfeng Zhao, Human Research Tissue Bank, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Addenbrooke's Hospital, United Kingdom
  • Lalarukh Haris Shaikh, Clinical Pharmacology Unit, Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, United Kingdom
  • Cheryl A Brighton, Clinical Pharmacology Unit, Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, United Kingdom
  • Ada E D Teo, Clinical Pharmacology Unit, Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, United Kingdom
  • Anthony P Davenport, Clinical Pharmacology Unit, Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, United Kingdom
  • Tanja Dekkers, Department of Internal Medicine, Radboud University Nijmegen Medical Centre, Netherlands
  • Bas Tops, Department of Pathology, Radboud University Nijmegen Medical Centre, Netherlands
  • Benno Küsters, Department of Pathology, Radboud University Nijmegen Medical Centre, United Kingdom
  • Jiri Ceral, 1st Department of Internal Medicine–Cardioangiology, Charles University Faculty of Medicine in Hradec Kralove and University Hospital Hradec Kralove, Czech Republic
  • Giles S H Yeo, University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Hospital, United Kingdom
  • Sudeshna Guha Neogi, Cambridge National Institute for Health Research (NIHR) Biomedical Research Centre (BRC), Department of Clinical Biochemistry, Addenbrooke's Hospital, United Kingdom
  • Ian McFarlane, Cambridge National Institute for Health Research (NIHR) Biomedical Research Centre (BRC), Department of Clinical Biochemistry, Addenbrooke's Hospital, United Kingdom
  • Nitzan Rosenfeld, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, United Kingdom
  • Francesco Marass, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, United Kingdom
  • James Hadfield, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, United Kingdom
  • Wojciech Margas, Department of Neuroscience, Physiology and Pharmacology, University College London, United Kingdom
  • Kanchan Chaggar, Department of Neuroscience, Physiology and Pharmacology, University College London, United Kingdom
  • Miroslav Solar, 1st Department of Internal Medicine–Cardioangiology, Charles University Faculty of Medicine in Hradec Kralove and University Hospital Hradec Kralove, Czech Republic
  • Jaap Deinum, Department of Internal Medicine, Radboud University Nijmegen Medical Centre, Netherlands
  • Annette C Dolphin, Department of Neuroscience, Physiology and Pharmacology, University College London, United Kingdom
  • I Sadaf Farooqi, University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Hospital, United Kingdom
  • Joerg Striessnig, Pharmacology and Toxicology, Institute of Pharmacy, Center for Molecular Biosciences, University of Innsbruck, Austria
  • Poul Nissen
  • Morris J Brown, Clinical Pharmacology Unit, Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, United Kingdom
At least 5% of individuals with hypertension have adrenal aldosterone-producing adenomas (APAs). Gain-of-function mutations in KCNJ5 and apparent loss-of-function mutations in ATP1A1 and ATP2A3 were reported to occur in APAs. We find that KCNJ5 mutations are common in APAs resembling cortisol-secreting cells of the adrenal zona fasciculata but are absent in a subset of APAs resembling the aldosterone-secreting cells of the adrenal zona glomerulosa. We performed exome sequencing of ten zona glomerulosa-like APAs and identified nine with somatic mutations in either ATP1A1, encoding the Na(+)/K(+) ATPase α1 subunit, or CACNA1D, encoding Cav1.3. The ATP1A1 mutations all caused inward leak currents under physiological conditions, and the CACNA1D mutations induced a shift of voltage-dependent gating to more negative voltages, suppressed inactivation or increased currents. Many APAs with these mutations were
Original languageEnglish
JournalNature Genetics
Volume45
Issue9
Pages (from-to)1055-1060
Number of pages6
ISSN1061-4036
DOIs
Publication statusPublished - 28 Aug 2013

See relations at Aarhus University Citationformats

ID: 56336129